AI Article Synopsis
- The study investigates DKK1 as a potential biomarker for early detection and prognosis of pancreatic cancer by comparing serum levels in patients with pancreatic adenocarcinoma and controls.
- DKK1 levels were found to be significantly higher in pancreatic cancer patients, especially in early stages, and showed better effectiveness than the common biomarker CA19-9 in distinguishing cancer from non-cancer cases.
- Higher DKK1 serum levels were associated with lower overall survival rates, suggesting it could serve as an important diagnostic and prognostic tool for pancreatic cancer.
Article Abstract
Purpose: To identify whether Dickkopf-1 (DKK1) could be a potential biomarker for early detection and prognosis in patients with pancreatic cancer (PC).
Methods: Serum was collected from 140 patients with pancreatic adenocarcinoma and 92 control patients without pancreatic adenocarcinoma. Serological levels of DKK1 were examined by enzyme-linked immunosorbent assay (ELISA). The sensitivity and specificity was compared with carbohydrate antigen 19-9 (CA19-9). A 2-year follow-up was monitored to evaluate the correlation between DKK1 serum levels and overall survival. The expression of DKK1 in PC tumor tissues was also evaluated using immunohistochemistry staining.
Results: Serum levels of DKK1 and CA19-9 were elevated in PC patients in the early-stage cases. These levels increased with the advancement of clinical stage. There was significant difference in DKK1 serum levels between early and advanced PC stages. Receiver operating characteristic curve (ROCC) analysis showed that DKK1 was significantly better than CA19-9 in differentiating patients with PC from the controls (area under the curve (AUC) 0.919 versus 0.853, respectively), especially in distinguishing early-stage cancer from chronic pancreatitis (CP). The expression of DKK1 in PC tissues correlated with its expression in serum samples. The overall survival rate was 24.4% in the group with higher DKK1 levels and was found to be significantly different from the group with lower DKK1 levels (33.3%).
Conclusion: DKK1 may be a novel diagnostic/prognostic biomarker for PC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637329 | PMC |
| http://dx.doi.org/10.18632/oncotarget.4529 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypothermia-associated acute pancreatitis: A multicenter prospective observational study.
Acute Med Surg
January 2025
Division of Acute and Critical Care Medicine, Department of Anaesthesiology and Critical Care Medicine Hokkaido University Graduate School of Medicine Sapporo Japan.
Aim: Hypothermia-associated pancreatitis lacks comprehensive understanding owing to limited studies exploring its mechanism, epidemiology, risk factors, and outcomes. We aimed to investigate the frequency, characteristics, and predictive factors associated with the development of acute pancreatitis in patients with accidental hypothermia.
Methods: This study comprised a post hoc analysis of data from a multicenter prospective observational study (ICE-CRASH study) conducted in 36 tertiary emergency hospitals in Japan.
Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma.
Mol Clin Oncol
February 2025
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Oita 879-5593, Japan.
Currently, neoadjuvant chemotherapy (NAC) is usually performed even for resectable pancreatic ductal adenocarcinoma (rPDAC). The present study investigated the benefits of NAC with gemcitabine plus S-1 for rPDAC. The medical records of 170 patients diagnosed as having rPDAC based on preoperative imaging were reviewed retrospectively.
View Article and Find Full Text PDFCurative resection of multiple primary neuroendocrine tumors enabled by preoperative imaging: a case report.
J Surg Case Rep
January 2025
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Neuroendocrine tumors (NENs) originate from neuroendocrine cells and predominantly occur in the gastrointestinal tract, lungs, and pancreas. Although the liver is commonly involved in NEN metastasis, primary hepatic neuroendocrine tumors (PHNETs) are rare. Herein, we report a case of a 52-year-old female who presented with slowly enlarging, cystic, multiple PHNETs.
View Article and Find Full Text PDFOptical molecular imaging technology and its application in precise surgical navigation of liver cancer.
Theranostics
January 2025
State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen 361002, China.
Recent innovations in medical imaging technology have placed molecular imaging techniques at the forefront of diagnostic advancements. The current research trajectory in this field aims to integrate personalized molecular data of patients and diseases with traditional anatomical imaging data, enabling more precise, non-invasive, or minimally invasive diagnostic options for clinical medicine. This article provides an in-depth exploration of the basic principles and system components of optical molecular imaging technology.
View Article and Find Full Text PDFIntroduction: A pancreatic neuroendocrine tumour (NET) originates from the neuroendocrine cells responsible for producing and releasing hormones. They are uncommon findings, mainly seen arising from the head of the pancreas and their appearances may vary among different imaging modalities.
Case Report: Interesting case of an asymptomatic patient with an incidental finding of a pancreatic lesion and its variable appearances across different modalities and final histology findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!